Indiana business leaders form coalition to boost civic engagement
The group hopes to improve civic education in a state that ranks among the bottom nationally when it comes to voter registration and turnout.
Eli Lilly and Co.
-
Lilly to install $10M worth of solar panels at two Indianapolis campuses
The solar structures are designed to help generate power for the company and reduce its carbon footprint.
Read More -
Eli Lilly sues businesses selling knockoff versions of Mounjaro
Lilly is suing medical spas, wellness centers and compounding pharmacies in various U.S. states that sell unapproved versions of its blockbuster diabetes drug, which is frequently used off-label for weight loss.
Read More -
Lilly stock skyrockets, raising profile of city’s life sciences sector
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
Read More -
Lilly reports surging profit, raises full-year guidance
The Indianapolis-based pharmaceutical company’s first-quarter performance was driven by strong sales of leading drugs for diabetes, cancer and other diseases.
Read More
Articles
Eli Lilly’s Jardiance among 10 prescription drugs chosen for price negotiations
The Biden administration is targeting diabetes treatment Jardiance and nine other medications for Medicare’s first-ever drug price negotiations as it seeks to lower medical costs for Americans.
Lilly stock soars to all-time high on strong sales, led by Mounjaro
Much of the excitement is due to strong results from Mounjaro, which hit the market in June 2022 as a treatment for Type 2 diabetes and rang up $979.7 million in the quarter.
New research shows Lilly drug slows decline in Alzheimer’s patients
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
Alzheimer’s caregivers watching closely as drugs finally hit market
More than 110,000 Hoosiers suffer from Alzheimer’s disease, which robs people of their memories and abilities to do daily tasks, and is the nation’s sixth-leading cause of death.
Lilly to spend up to $1.93 billion to acquire Boston biopharmaceutical firm
With the acquisition of Versanis Bio, Lilly is adding another promising treatment to its weight-loss drug pipeline.
Weight-loss drugs probed over reports of suicidal thoughts
The EMA said it would consider whether its review should be extended to other drugs in the same class, known as GLP-1 receptor agonists. Indianapolis-based Eli Lilly and Co.’s Mounjaro is among them.
IBJ Podcast: Lilly in middle of big battle over future of drug prices for seniors
In this week’s edition of the IBJ Podcast, reporter John Russell discusses Medicare’s new power to negotiate drug prices and its effects on patients, drug makers and the rest the health care industry. Eli Lilly and Co. would like to see some changes.
Drugmakers warn new law will deter discoveries
David Ricks, CEO of Indianapolis-based drugmaker Eli Lilly and Co., is turning up the volume on his concerns over a new law that would allow Medicare, for the first time, to negotiate drug prices.
Eli Lilly to acquire Massachusetts-based biotech for $309M
The Indianapolis-based drugmaker said it will acquire Sigilon Therapeutics Inc., a six-year-old startup that is developing a technology to help type 1 diabetes patients restore insulin production over sustained periods.
Next step for obesity drug makers replacing needles with pills
Medical experts predict the pills will be popular, especially among people who want to lose weight but are fearful of needles.
Insurers clamping down on doctors who prescribe Ozempic for weight loss
Indianapolis-based Elevance Health, which operates Anthem plans, said that in most cases, it won’t cover Ozempic unless a patient is diagnosed with diabetes and has tried another medication to manage it, but physicians can still prescribe it.
Lilly battling rivals for breast-cancer patients
The Indianapolis-based pharmaceutical giant is spending hundreds of millions of dollars to win over patients with an extensive advertising campaign.
Medicare to expand coverage for new class of costly Alzheimer’s drugs
Groups such as the Alzheimer’s Association have pushed Medicare to cover the new Alzheimer’s drugs—including those cleared on an expedited basis—saying that the FDA should be the final arbiter of safety and efficacy of drugs.
Eli Lilly settles class-action insulin lawsuit for $13.5M
Under the agreement, Lilly has agreed to continue its cap on out-of-pocket costs for its users at $35 a month for four years.
Federal judge triples damages to $183M against Lilly in whistleblower suit
A judge ruled that Indianapolis-based Lilly was liable for higher payments due to its behavior in making false statements to the Centers for Medicare and Medicaid Services about the prices it charged distributors for its drugs.
Eli Lilly says experimental drug slows decline from Alzheimer’s
If approved, Donanemab has annual multi-billion-dollar sales potential. Lilly shares rose 6% in early-afternoon trading.
Coming off record fundraising year, Indiana’s life science sector looks for even more capital in 2023
Inventors and entrepreneurs who don’t have a track record face the biggest challenges, a panel of experts said Friday morning at IBJ’s Life Sciences Power Breakfast.
Powerful new obesity drug poised to upend weight-loss care
If approved for weight loss, Eli Lilly’s tirzepatide could become the most effective drug to date in an arsenal of medications that are transforming the treatment of obesity, which affects more than 4 in 10 American adults and is linked to dozens of diseases.
Lilly diabetes drug helps patients shed average of 34 pounds, a development sure to boost sales
The Indianapolis-based drugmaker said it would complete submission of tirzepatide to the U.S. Food and Drug Administration in coming weeks for treatment of obesity and expects regulatory action as early as late 2023.